[go: up one dir, main page]

CR8787A - TIENO (3,2-b) PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA - Google Patents

TIENO (3,2-b) PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA

Info

Publication number
CR8787A
CR8787A CR8787A CR8787A CR8787A CR 8787 A CR8787 A CR 8787A CR 8787 A CR8787 A CR 8787A CR 8787 A CR8787 A CR 8787A CR 8787 A CR8787 A CR 8787A
Authority
CR
Costa Rica
Prior art keywords
carbonitrils
tieno
piridin
inhibitors
protein kinase
Prior art date
Application number
CR8787A
Other languages
English (en)
Inventor
Diane Harris Boschelli
Nan Zhang
Sosa Ana Carolina Barrios
Haris Durutlic
Biqi Wu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8787A publication Critical patent/CR8787A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

Esta invencion provee los compuestos de la formula II en la cual R1,R2 y X son definidos en lo que antecede en la memoria descriptiva, los cuales son utiles en el tratamiento del cancer, ataque apopletico, infarto de miocardio dolor neuropatico, osteoporosis, enfermedad renal policistica, enfermedad autoinmune, artritis reumatoidea y rehcazo de transplantes. La invencion tambien provee procesos para producir dichos compuestos.
CR8787A 2004-05-14 2006-12-05 TIENO (3,2-b) PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA CR8787A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/845,710 US7276519B2 (en) 2002-11-25 2004-05-14 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
CR8787A true CR8787A (es) 2007-10-02

Family

ID=35149207

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8787A CR8787A (es) 2004-05-14 2006-12-05 TIENO (3,2-b) PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA

Country Status (20)

Country Link
US (2) US7276519B2 (es)
EP (1) EP1756117A2 (es)
JP (1) JP2007537262A (es)
KR (1) KR20070015575A (es)
CN (1) CN1950379A (es)
AR (1) AR050248A1 (es)
AU (1) AU2005245820A1 (es)
BR (1) BRPI0511089A (es)
CA (1) CA2564530A1 (es)
CR (1) CR8787A (es)
EC (1) ECSP067087A (es)
GT (1) GT200500109A (es)
MX (1) MXPA06012900A (es)
NO (1) NO20065489L (es)
PA (1) PA8633201A1 (es)
PE (1) PE20060355A1 (es)
RU (1) RU2006137476A (es)
TW (1) TW200602348A (es)
WO (1) WO2005113560A2 (es)
ZA (1) ZA200609422B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1833829A2 (en) 2004-12-23 2007-09-19 F. Hoffmann-Roche AG Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
US7786113B2 (en) * 2004-12-23 2010-08-31 Hoffman-La Roche Inc. Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
WO2007073555A1 (en) * 2005-12-20 2007-06-28 Gilead Colorado, Inc. Use of 4, 7-dihydrothieno [2, 3-b] pyridine compounds in the treatment of cardiovascular diseases
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
WO2008108309A1 (ja) * 2007-03-02 2008-09-12 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
WO2009041591A1 (ja) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
DK2331530T3 (da) * 2008-09-26 2013-11-11 Nat Health Research Institutes Kondenserede multicycliske forbindelser som proteinkinaseinhibitorer
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
HRP20161578T1 (hr) * 2012-02-09 2016-12-30 Merck Patent Gmbh Derivati furo[3, 2-b]piridina kao inhibitori tbk1 i ikk
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126970A3 (en) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ID23978A (id) 1997-11-11 2000-06-14 Pfizer Prod Inc Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker
EP1950201A1 (en) * 1998-09-29 2008-07-30 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
DE60009888T2 (de) 1999-04-21 2005-04-21 Wyeth Corp Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
WO2001047892A1 (en) 1999-12-29 2001-07-05 Wyeth Tricyclic protein kinase inhibitors
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
WO2001094353A1 (en) 2000-06-06 2001-12-13 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
AU2001295791A1 (en) * 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
EP1418917A1 (en) 2001-08-10 2004-05-19 Novartis AG Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006343808B2 (en) * 2005-05-20 2012-03-29 Mirati Therapeutics, Inc. Inhibitors of VEGF receptor and HGF receptor signaling
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA

Also Published As

Publication number Publication date
TW200602348A (en) 2006-01-16
KR20070015575A (ko) 2007-02-05
CN1950379A (zh) 2007-04-18
US7276519B2 (en) 2007-10-02
BRPI0511089A (pt) 2007-12-26
WO2005113560A3 (en) 2006-01-12
ECSP067087A (es) 2007-01-26
AR050248A1 (es) 2006-10-11
WO2005113560A2 (en) 2005-12-01
JP2007537262A (ja) 2007-12-20
US20080070913A1 (en) 2008-03-20
MXPA06012900A (es) 2007-01-26
RU2006137476A (ru) 2008-06-20
NO20065489L (no) 2006-11-28
AU2005245820A1 (en) 2005-12-01
ZA200609422B (en) 2008-07-30
PA8633201A1 (es) 2006-05-16
CA2564530A1 (en) 2005-12-01
GT200500109A (es) 2005-12-23
US20040242883A1 (en) 2004-12-02
PE20060355A1 (es) 2006-05-11
EP1756117A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
ECSP055802A (es) TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS Y TIENO[2,3-b]PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINA CINASAS
CR8787A (es) TIENO (3,2-b) PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA
SV2002000572A (es) 2- (4-piridil) animo- 6- dialcoxifenil-pirido [2,3-d] pirimidin-7-onas
PE20151336A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR061568A1 (es) Compuestos
ECSP056072A (es) Pirimidinonas sustituidas
CR8410A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
CL2012002501A1 (es) Compuestos derivados de 4-(1-(1-(piperidin-4-il)azetidin-3-il)-h-pirazol-4-il)-(1h-pirrolo[2,3-b]piridina o pirimidina); forma cristalina; composicion farmaceutica; util para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, enfermedad inflamatoria, de resorcion osea o rechazo al trasplante.
BRPI0508622A (pt) compostos de bifenil úteis como antagonistas do receptor muscarìnico
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
UY27225A1 (es) Inhibidores de la rho-quinasa
NZ600631A (en) Heteroaryl compounds and uses thereof
CY1112117T1 (el) Υδροξυλιωμενες και μεθοξυλιωμενες κυκλοπεντα[d]πυριμιδινες ως αναστολεις ακτ πρωτεϊνικης κινασης
GT200500101A (es) Compuestos de metil-aril o heteroaril-amida sustituida
GT200300289A (es) Derivados de pirrolopirimidina
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
PE20080974A1 (es) Nuevas pirozolopirimidinas como inhibidores de quinasa dependientes de ciclina
GT200500296A (es) Sintesis asimetrica de derivados del dehidrobenzofurano
PE20070621A1 (es) 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
CR8749A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
CR8562A (es) Procedimiento para la preparacion de compuestos de triazol sustituidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)